All Is Well With ACRS, First Avastin Biosimilar In The Works, CLRB Abuzz

Shares of Aclaris Therapeutics Inc. were up more than 6% in extended trading on Tuesday, following positive results from two pivotal phase III trials of its lead product candidate A-101 40% Topical Solution for the treatment of seborrheic keratosis.

from RTT - Biotech http://ift.tt/2fvTOiA
via IFTTT